Avanos Medical, Inc. (AVNS)

$22.51

+0.52

(+2.36%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $21.71
    $22.57
    $22.51
    downward going graph

    3.55%

    Downside

    Day's Volatility :3.81%

    Upside

    0.27%

    downward going graph
  • $17.24
    $25.62
    $22.51
    downward going graph

    23.41%

    Downside

    52 Weeks Volatility :32.71%

    Upside

    12.14%

    downward going graph

Returns

PeriodAvanos Medical, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
19.99%
5.3%
0.0%
6 Months
15.61%
6.3%
0.0%
1 Year
-11.86%
9.2%
0.0%
3 Years
-35.22%
13.1%
-19.9%

Highlights

Market Capitalization
1.0B
Book Value
$26.58
Earnings Per Share (EPS)
-0.03
Wall Street Target Price
23.5
Profit Margin
-9.15%
Operating Margin TTM
4.51%
Return On Assets TTM
2.18%
Return On Equity TTM
-0.13%
Revenue TTM
680.1M
Revenue Per Share TTM
14.63
Quarterly Revenue Growth YOY
4.3%
Gross Profit TTM
450.0M
EBITDA
104.7M
Diluted Eps TTM
-0.03
Quarterly Earnings Growth YOY
-0.37
EPS Estimate Current Year
1.37
EPS Estimate Next Year
1.81
EPS Estimate Current Quarter
0.21
EPS Estimate Next Quarter
0.28

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Avanos Medical, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 4.4%

Current $22.51
Target $23.50

Company Financials

FY18Y/Y Change
Revenue
652.3M
↑ 6.65%
Net Income
57.5M
↓ 27.49%
Net Profit Margin
8.81%
↓ 4.16%
FY19Y/Y Change
Revenue
697.6M
↑ 6.94%
Net Income
-45.9M
↓ 179.83%
Net Profit Margin
-6.58%
↓ 15.39%
FY20Y/Y Change
Revenue
714.8M
↑ 2.47%
Net Income
-27.2M
↓ 40.74%
Net Profit Margin
-3.81%
↑ 2.77%
FY21Y/Y Change
Revenue
744.6M
↑ 4.17%
Net Income
6.3M
↓ 123.16%
Net Profit Margin
0.85%
↑ 4.66%
FY22Y/Y Change
Revenue
820.0M
↑ 10.13%
Net Income
50.5M
↑ 701.59%
Net Profit Margin
6.16%
↑ 5.31%
FY23Y/Y Change
Revenue
673.3M
↓ 17.89%
Net Income
-61.8M
↓ 222.38%
Net Profit Margin
-9.18%
↓ 15.34%
Q4 FY22Q/Q Change
Revenue
217.5M
↑ 7.62%
Net Income
16.9M
↑ 7.64%
Net Profit Margin
7.77%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
191.7M
↓ 11.86%
Net Income
-500.0K
↓ 102.96%
Net Profit Margin
-0.26%
↓ 8.03%
Q2 FY23Q/Q Change
Revenue
169.4M
↓ 11.63%
Net Income
-68.1M
↑ 13520.0%
Net Profit Margin
-40.2%
↓ 39.94%
Q3 FY23Q/Q Change
Revenue
171.3M
↑ 1.12%
Net Income
-3.7M
↓ 94.57%
Net Profit Margin
-2.16%
↑ 38.04%
Q4 FY23Q/Q Change
Revenue
173.3M
↑ 1.17%
Net Income
10.5M
↓ 383.78%
Net Profit Margin
6.06%
↑ 8.22%
Q1 FY24Q/Q Change
Revenue
166.1M
↓ 4.15%
Net Income
-900.0K
↓ 108.57%
Net Profit Margin
-0.54%
↓ 6.6%
FY18Y/Y Change
Total Assets
1.8B
↓ 16.51%
Total Liabilities
536.2M
↓ 45.31%
FY19Y/Y Change
Total Assets
1.8B
↓ 1.84%
Total Liabilities
534.4M
↓ 0.34%
FY20Y/Y Change
Total Assets
1.7B
↓ 7.05%
Total Liabilities
416.3M
↓ 22.1%
FY21Y/Y Change
Total Assets
1.6B
↓ 4.67%
Total Liabilities
330.7M
↓ 20.56%
FY22Y/Y Change
Total Assets
1.8B
↑ 12.06%
Total Liabilities
495.7M
↑ 49.89%
FY23Y/Y Change
Total Assets
1.7B
↓ 5.29%
Total Liabilities
456.1M
↓ 7.99%
Q4 FY22Q/Q Change
Total Assets
1.8B
↑ 0.66%
Total Liabilities
495.7M
↓ 3.13%
Q1 FY23Q/Q Change
Total Assets
1.7B
↓ 2.91%
Total Liabilities
436.2M
↓ 12.0%
Q2 FY23Q/Q Change
Total Assets
1.7B
↓ 3.93%
Total Liabilities
431.9M
↓ 0.99%
Q3 FY23Q/Q Change
Total Assets
1.7B
↑ 3.49%
Total Liabilities
502.8M
↑ 16.42%
Q4 FY23Q/Q Change
Total Assets
1.7B
↓ 1.88%
Total Liabilities
456.1M
↓ 9.29%
Q1 FY24Q/Q Change
Total Assets
1.7B
↓ 1.84%
Total Liabilities
433.4M
↓ 4.98%
FY18Y/Y Change
Operating Cash Flow
-145.6M
↓ 200.97%
Investing Cash Flow
639.5M
↓ 1583.76%
Financing Cash Flow
-324.4M
↓ 14845.45%
FY19Y/Y Change
Operating Cash Flow
-74.5M
↓ 48.83%
Investing Cash Flow
-108.1M
↓ 116.9%
Financing Cash Flow
1.5M
↓ 100.46%
FY20Y/Y Change
Operating Cash Flow
-2.5M
↓ 96.64%
Investing Cash Flow
-24.2M
↓ 77.61%
Financing Cash Flow
-70.0M
↓ 4766.67%
FY21Y/Y Change
Operating Cash Flow
87.3M
↓ 3592.0%
Investing Cash Flow
-21.0M
↓ 13.22%
Financing Cash Flow
-55.3M
↓ 21.0%
FY22Y/Y Change
Operating Cash Flow
90.9M
↑ 4.12%
Investing Cash Flow
-135.4M
↑ 544.76%
Financing Cash Flow
56.7M
↓ 202.53%
Q4 FY22Q/Q Change
Operating Cash Flow
33.7M
↑ 18.66%
Investing Cash Flow
-4.9M
↑ 4.26%
Financing Cash Flow
-21.9M
↑ 114.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.8M
↓ 120.18%
Investing Cash Flow
-4.0M
↓ 18.37%
Financing Cash Flow
-22.1M
↑ 0.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 61.76%
Investing Cash Flow
-6.5M
↑ 62.5%
Financing Cash Flow
-4.1M
↓ 81.45%
Q3 FY23Q/Q Change
Operating Cash Flow
29.1M
↓ 1219.23%
Investing Cash Flow
-48.9M
↑ 652.31%
Financing Cash Flow
46.7M
↓ 1239.02%

Technicals Summary

Sell

Neutral

Buy

Avanos Medical, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avanos Medical, Inc.
Avanos Medical, Inc.
16.45%
15.61%
-11.86%
-35.22%
-44.23%
Stryker Corporation
Stryker Corporation
0.98%
9.68%
17.77%
30.35%
63.53%
Boston Scientific Corp.
Boston Scientific Corp.
2.03%
29.12%
50.03%
77.4%
82.53%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.42%
17.59%
-3.73%
-19.57%
35.05%
Abbott Laboratories
Abbott Laboratories
-1.5%
-9.02%
-9.51%
-14.14%
16.88%
Medtronic Plc
Medtronic Plc
-2.15%
-8.15%
-10.66%
-38.31%
-21.96%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avanos Medical, Inc.
Avanos Medical, Inc.
52.7
NA
NA
1.37
0.0
0.02
NA
26.58
Stryker Corporation
Stryker Corporation
38.92
38.92
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.18
65.18
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.93
37.93
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.19
32.19
5.99
4.64
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.8
28.8
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avanos Medical, Inc.
Avanos Medical, Inc.
Buy
$1.0B
-44.23%
52.7
-9.15%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
63.53%
38.92
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.0B
82.53%
65.18
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$53.0B
35.05%
37.93
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.5B
16.88%
32.19
13.65%
Medtronic Plc
Medtronic Plc
Buy
$101.9B
-21.96%
28.8
11.36%

Insights on Avanos Medical, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 173.3M → 166.1M (in $), with an average decrease of 4.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 10.5M → -900.0K (in $), with an average decrease of 108.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 47.2% return, outperforming this stock by 57.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 77.4% return, outperforming this stock by 112.6%

Institutional Holdings

  • BlackRock Inc

    15.81%
  • Vanguard Group Inc

    11.76%
  • RGM Capital LLC

    6.91%
  • Dimensional Fund Advisors, Inc.

    5.84%
  • Westwood Holdings Group Inc

    4.61%
  • State Street Corporation

    4.30%

Company Information

avanos is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter.headquartered in alpharetta, georgia, avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.avanos develops, manufactures and markets its recognized brands in more than 90 countries.

Organization
Avanos Medical, Inc.
Employees
3771
CEO
Mr. Joseph F. Woody
Industry
Health Technology

FAQs